| 95.5 3.52 (3.83%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 120.13  |
1-year : | 140.31 |
| Resists | First : | 102.85 |
Second : | 120.13 |
| Pivot price | 89.43  |
|||
| Supports | First : | 88.43 |
Second : | 79.51 |
| MAs | MA(5) : | 92.09 |
MA(20) : | 89.87 |
| MA(100) : | 99.99 |
MA(250) : | 102.95 |
|
| MACD | MACD : | -1.8 |
Signal : | -3.1 |
| %K %D | K(14,3) : | 88 |
D(3) : | 74.4 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 124 | Low : | 79.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BNTX ] has closed Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 96.09 - 96.55 | 96.55 - 96.96 |
| Low: | 91.19 - 91.72 | 91.72 - 92.18 |
| Close: | 94.69 - 95.53 | 95.53 - 96.25 |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Sat, 11 Apr 2026
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan
Fri, 10 Apr 2026
BioNTech (BNTX) Analyst Ratings Update: April 10, 2026 | BNTX St - GuruFocus
Tue, 07 Apr 2026
Is BioNTech (BNTX) Quietly Rewriting Its Investment Story Around Oncology Beyond COVID Vaccines? - simplywall.st
Tue, 07 Apr 2026
Leerink cuts BioNTech stock price target on drug trial concerns - Investing.com
Thu, 02 Apr 2026
BioNTech (NASDAQ: BNTX) outlines virtual 2026 AGM, board expansion and 50% capital authority - Stock Titan
Tue, 31 Mar 2026
BioNTech shares plunge over 19% after fourth-quarter earnings miss - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 251 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 55.1 (%) |
| Held by Institutions | 19.6 (%) |
| Shares Short | 3,540 (K) |
| Shares Short P.Month | 4,720 (K) |
| EPS | -5.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 88.23 |
| Profit Margin | -39.6 % |
| Operating Margin | -33.4 % |
| Return on Assets (ttm) | -3.6 % |
| Return on Equity (ttm) | -5.9 % |
| Qtrly Rev. Growth | -23.8 % |
| Gross Profit (p.s.) | 8.99 |
| Sales Per Share | 11.41 |
| EBITDA (p.s.) | -4.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 456 (M) |
| Levered Free Cash Flow | -1,100 (M) |
| PE Ratio | -17.59 |
| PEG Ratio | 0 |
| Price to Book value | 1.08 |
| Price to Sales | 8.36 |
| Price to Cash Flow | 52.63 |
| Dividend | 2.1 |
| Forward Dividend | 0 |
| Dividend Yield | 2.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|